Fresenius Medical Care (FME.DE) Aktie Kurs
Fresenius Medical Care Kurs
Omsætningen er vokset med 6,0 % om året de seneste 19 år til 19,63 Mrd. EUR. Indtjening pr. aktie er vokset med 4,9 % om året de seneste 19 år. Fresenius Medical Cares nettoavance ligger på 5,0 %, overvejende stabil fra 5,5 % for flere år siden. Fresenius Medical Care har i øjeblikket et direkteafkast på omkring 3,54 %. Udlodningsandelen er omkring 42 % af indtjeningen. Udbyttet er vokset med 6,8 % om året de seneste 19 år. Analytikernes mediankursmål er 46,92 EUR, hvilket er over den aktuelle kurs med 15,4 %. Af 27 analytikere anbefaler 11 køb — den samlede vurdering er Hold.
Fresenius Medical Care aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Fresenius Medical Care aktie og aktieanalyse
Hyppigt stillede spørgsmål om Fresenius Medical Care-aktien
Fresenius Medical Care AG is a leading global provider of dialysis products, services, and solutions for patients with chronic kidney failure. The company's business model revolves around providing high-quality dialysis care to patients in over 120 countries. Fresenius Medical Care AG offers a comprehensive range of dialysis machines, dialyzers, and other related products to ensure efficient and effective treatment. Furthermore, the company operates a network of dialysis clinics, providing personalized care for patients worldwide. With a focus on innovation, research, and development, Fresenius Medical Care AG continuously strives to enhance patient outcomes and improve the overall quality of life for individuals with kidney disease.
Fresenius Medical Care AG is primarily active in the healthcare industry.
The main competitors of Fresenius Medical Care AG in the market are DaVita Inc., Baxter International Inc., and B. Braun Melsungen AG.
Fresenius Medical Care AG is a leading global healthcare company specializing in dialysis products and services. Established in 1996, it stemmed from the merger of Fresenius AG and National Medical Care. With its headquarters in Germany, the company has expanded its reach worldwide, operating in nearly 150 countries. Fresenius Medical Care AG is renowned for its expertise in renal therapy, offering innovative dialysis machines, dialyzers, and related medical supplies. As a market leader, it provides life-saving treatments to millions of people suffering from chronic kidney disease. The company's commitment to delivering high-quality care and advancing renal healthcare has made Fresenius Medical Care AG a trusted name in the medical industry.
Fresenius Medical Care AG, a leading healthcare company, has achieved significant milestones throughout its history. It pioneered the development of advanced dialysis products and services, revolutionizing the treatment of end-stage renal disease. The company has established a global presence, operating in over 120 countries and serving millions of patients worldwide. Additionally, Fresenius Medical Care AG has continuously expanded its business through strategic acquisitions and collaborations, strengthening its position as a market leader in dialysis care. With a commitment to research and development, the company has achieved breakthrough innovations in dialysis technology, enhancing patient outcomes and quality of life. Overall, Fresenius Medical Care AG’s impressive achievements have solidified its reputation as a trusted provider of renal therapies.
Fresenius Medical Care AG is primarily present in various countries and regions across the globe. With a strong global presence, the company operates in more than 150 countries and regions, including the United States, Germany, Asia-Pacific, Latin America, and Europe. Its widespread international network enables Fresenius Medical Care AG to provide advanced renal care products, services, and solutions to patients worldwide. As the global leader in dialysis and kidney care, Fresenius Medical Care AG continues to expand its reach and impact, ensuring quality healthcare for patients globally.
Fresenius Medical Care AG represents values of quality, innovation, and patient-centered care. With a dedicated corporate philosophy, the company focuses on providing life-saving dialysis products, therapies, and services to patients worldwide. The commitment to excellence, compassion, and continuous advancement in medical technology enables Fresenius Medical Care AG to enhance patients' quality of life and deliver optimal renal care. As a global leader in the field, Fresenius Medical Care AG maintains a strong emphasis on scientific research, sustainability, and delivering efficient healthcare solutions for patients suffering from chronic kidney diseases.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 45,79 EUR for Fresenius Medical Care-aktien (median: 46,92 EUR), svarende til +12,6 % i forhold til seneste kurs. Konsensus bygger på 27 analytikervurderinger.
27 analytikere vurderer i øjeblikket Fresenius Medical Care-aktien: 11 anbefaler køb, 9 hold og 7 salg. For 2026 forventer analytikere, at Fresenius Medical Care genererer omsætning på 19,46 Mrd. EUR og indtjening pr. aktie på 4,18 EUR.
Fresenius Medical Care-aktien (FME.DE) er noteret på 10 børser, herunder: London (0H9X.L), SIX (Zürich) (FMEEUR.SW), XETRA (FME.DE), Frankfurt (FME.F), München (FME.MU), Düsseldorf (FME.DU), Hamburg (FME.HM), Wien (FME.VI).
Fresenius Medical Care AG is a leading provider of products and services for the dialysis treatment of patients with kidney failure. The company is headquartered in Bad Homburg, Germany, and operates in over 120 countries worldwide. Fresenius Medical Care also operates its own dialysis centers and offers various other medical services. The business model of Fresenius Medical Care includes three business segments: dialysis products, services related to dialysis treatment, and the care of patients with chronic diseases. In the field of dialysis products, Fresenius Medical Care develops and produces a wide range of dialysis equipment and reagents. These products are sold to both their own dialysis centers and other medical facilities worldwide. Thanks to technological innovations in dialysis treatment, medical professionals can offer patients better outcomes and a higher quality of life. In the second business segment, Fresenius Medical Care provides services related to dialysis treatment. The company operates and manages its own dialysis centers and also provides the necessary medical professionals. Additionally, Fresenius Medical Care offers technical support and training for the use of their own dialysis products. These services are an important part of the business model as they ensure both the sales of their own products and the high-quality medical care of patients. A third business segment of Fresenius Medical Care is the care of patients with chronic diseases. Through the use of data analysis and telemedicine technologies, medical professionals from Fresenius Medical Care can actively care for patients - both online and through home visits. The goal is to improve the health of patients and avoid hospital stays. The business model of Fresenius Medical Care is based on preventive health care and support for people with chronic diseases such as kidney failure. By providing high-quality products and services and establishing a comprehensive patient care program, Fresenius Medical Care strengthens its position as a leading provider in dialysis treatment. In recent years, Fresenius Medical Care has also increased its investment in research and development of innovative treatment methods to continuously improve the quality of medical care for patients with chronic diseases. The extensive expertise in this field enables the development of new treatment modalities, including digital solutions, that benefit patients. Overall, Fresenius Medical Care is an innovative company specializing in the provision of products and services for dialysis treatment. By combining technological innovations, a comprehensive patient care program, and a constant focus on the needs of medical professionals in the global healthcare industry, the company relies on a forward-looking, promising business model in a sector of growing importance.
forventet-omsætningen for Fresenius Medical Care er 19,46 Mrd. EUR. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Fresenius Medical Care er 1,19 Mrd. EUR. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Fresenius Medical Care er i øjeblikket 9,73. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Fresenius Medical Care-aktien.
Pris-til-salgs-forholdet (P/S) for Fresenius Medical Care er i øjeblikket 0,60. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Fresenius Medical Care-aktien.
AlleAktien-kvalitetsscore for Fresenius Medical Care er 2/10.
ISIN for Fresenius Medical Care er DE0005785802. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Fresenius Medical Care er 578580. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Fresenius Medical Care er FME.DE. Tickersymbolet bruges til at handle Fresenius Medical Care-aktier på børsen.
Fresenius Medical Care aktie
Fresenius Medical Care Peer Group
Fresenius Medical Care Ticker
Fresenius Medical Care FIGI
Alle fundamentale data om Fresenius Medical Care i deep dive
Vores aktieanalyse af Fresenius Medical Care-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Fresenius Medical Care. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: